"Designing Growth Strategies is in our DNA"
Craniomaxillofacial surgeries are performed in order to treat diseases, injuries, defects, and abnormalities associated with head, neck, cranial space, and face. The craniomaxillofacial implant offers replacements and restoration of dysfunctional or missing anatomical structures in order to improve the function of defective craniomaxillofacial parts. Commonly observed craniomaxillofacial abnormalities include cleft lip, hemifacial macrosomia, craniosynostosis, hemangiomas, vascular malformations, and cleft palate.
Craniomaxillofacial abnormalities adversely affect eating habits, difficulties in speech and language, hearing loss, and dental problems. The craniomaxillofacial implant includes plates, meshes, screws, and other instruments. The emerging applications of certain software such as CAD (computer-aided design and drafting)/ CAM (Computer-aided manufacturing) for designing and manufacturing of craniomaxillofacial implants are likely to offer greater precision to the care providers.
To gain extensive insights into the market, Request for Customization
Global craniomaxillofacial implants market growth is being driven by the escalating incidence of craniomaxillofacial abnormalities in new born and rising number of craniomaxillofacial injuries due to accidents. Combined with this, growth in adoption of craniomaxillofacial implants for aesthetic purpose in developed nations is expected to boost the demand for craniomaxillofacial implants during the forecast period. According to the American Society of Craniofacial Surgeons, an estimated 1 in 1000 babies in born with cleft palate each year in the U.S., which is anticipated to boost the demand for craniomaxillofacial implants.
However, lack of craniomaxillofacial surgeons and proper healthcare infrastructure in emerging nations may hamper the growth in the global craniomaxillofacial implants market.
Some of the major companies that are present in the global craniomaxillofacial implants market report include Stryker, Medtronic, Integra LifeSciences, DePuy Synthes, Integer Holdings Corporation, KLS Martin Group, Medartis, Zimmer Biomet, B. Braun Melsungen AG, MATRIX SURGICAL USA, Rebstock Instruments GmbH, OsteoMed, Materialise, Johnson & Johnson Services, Inc., CONMED Corporation, Calavera Surgical Design, and others.
SEGMENTATION | DETAILS |
By Product | · Screws · Mesh · Plates · Bone Graft · Dural Repair · Others |
By Material | · Titanium · Polymers · Others |
By End User | · Hospitals · Clinics · Ambulatory Surgery Centres · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
As per the current craniomaxillofacial implants market trends, the titanium segment among the material is anticipated to hold a considerable share of the global craniomaxillofacial market during the forecast period owing to the high preference of titanium for manufacturing of implants, higher strength, and resistant to degradation.
The global craniomaxillofacial implants market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global craniomaxillofacial implants market over the forecast period owing to the rise in craniomaxillofacial disorders, favourable health reimbursement, and rapid adoption of 3D printing technology in the manufacturing of implants. The craniomaxillofacial market in Europe is expected to expand with considerable CAGR during the forecast period owing to new product launch and increasing incidences of sports injuries. Asia Pacific and Middle East & Africa are likely to leverage huge potential for growth of the global craniomaxillofacial implants market owing to the growing awareness regarding external and internal implants, increased healthcare investment, and active government support.
US +1 833 909 2966 ( Toll Free )